POCT for NT‐proBNP correctly identified the patients' risk category in a higher proportion of patients than BNP, suggesting NT‐proBNP POCT is the more reliable tool in the setting of PAH. This evidence concerns the gene NPPB and pulmonary arterial hypertension.